The US FDA has approved Neupro® (Rotigotine Transdermal System) for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease (PD). Neupro is a once-daily non-ergolinic dopamine agonist skin patch developed by Schwarz Pharma.
“This is an important step forward for the patients suffering from Parkinson’s disease. Following approval and launch within Europe, Neupro will now be available for patients in the USA”, comments Iris Loew-Friedrich, MD, PhD, CSO SCHWARZ PHARMA AG. “We intend to submit a supplemental New Drug Application for the treatment of advanced Parkinson’s disease to the FDA by the end of 2007.”